AU612054B2 - Peptides having bradykinin antagonist action - Google Patents
Peptides having bradykinin antagonist action Download PDFInfo
- Publication number
- AU612054B2 AU612054B2 AU39431/89A AU3943189A AU612054B2 AU 612054 B2 AU612054 B2 AU 612054B2 AU 39431/89 A AU39431/89 A AU 39431/89A AU 3943189 A AU3943189 A AU 3943189A AU 612054 B2 AU612054 B2 AU 612054B2
- Authority
- AU
- Australia
- Prior art keywords
- arg
- pro
- gly
- tic
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 79
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 37
- 230000009471 action Effects 0.000 title abstract description 7
- UYRCOTSOPWOSJK-JXTBTVDRSA-N bradykinin antagonist Chemical compound C1C2=CC=CC=C2CC1[C@@H](NC(=O)C(CO)NC(=O)C(NC(=O)CNC(=O)[C@H]1N(C[C@H](O)C1)C(=O)C1N(CCC1)C(=O)C(CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=N)CCCCCCC(=N)N[C@H](CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)N1C(CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)NC(C1CC2=CC=CC=C2C1)C(=O)NC(CO)C(=O)N[C@H](C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(N)=N)C(O)=O)C1CC2=CC=CC=C2C1)C(=O)N1C2CCCCC2CC1C(=O)NC(CCCNC(=N)N)C(O)=O UYRCOTSOPWOSJK-JXTBTVDRSA-N 0.000 title description 7
- 239000003152 bradykinin antagonist Substances 0.000 title description 7
- -1 aromatic amino acid Chemical class 0.000 claims abstract description 63
- 150000001413 amino acids Chemical class 0.000 claims abstract description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 9
- 125000003118 aryl group Chemical group 0.000 claims abstract description 8
- 102400000967 Bradykinin Human genes 0.000 claims abstract description 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims abstract description 7
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims abstract description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 7
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000001575 pathological effect Effects 0.000 claims abstract description 3
- 101710097732 Bradykinin-related peptides Proteins 0.000 claims abstract 3
- 235000001014 amino acid Nutrition 0.000 claims description 30
- 125000006239 protecting group Chemical group 0.000 claims description 24
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims description 2
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims description 2
- AXEOMQHKTSGLGS-VIFPVBQESA-N (2s)-2-amino-3-(4-hydroxy-2-methylphenyl)propanoic acid Chemical compound CC1=CC(O)=CC=C1C[C@H](N)C(O)=O AXEOMQHKTSGLGS-VIFPVBQESA-N 0.000 claims description 2
- PDELQDSYLBLPQO-JGVFFNPUSA-N (3as,7ar)-2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCC[C@H]2NCC[C@@H]21 PDELQDSYLBLPQO-JGVFFNPUSA-N 0.000 claims description 2
- NENLYAQPNATJSU-IUCAKERBSA-N (4as,8ar)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCC[C@@H]2CCCC[C@H]21 NENLYAQPNATJSU-IUCAKERBSA-N 0.000 claims description 2
- NENLYAQPNATJSU-DTWKUNHWSA-N (4as,8as)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCC[C@@H]2CCCC[C@@H]21 NENLYAQPNATJSU-DTWKUNHWSA-N 0.000 claims description 2
- CVZZNRXMDCOHBG-UHFFFAOYSA-N 2-azaniumyl-3-(2-chlorophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=CC=C1Cl CVZZNRXMDCOHBG-UHFFFAOYSA-N 0.000 claims description 2
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 claims description 2
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- JJDJLFDGCUYZMN-QMMMGPOBSA-N 3-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(Cl)=C1 JJDJLFDGCUYZMN-QMMMGPOBSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 claims description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- UNNHOBJPTGBVJQ-UHFFFAOYSA-N C1NCCC2=CC=CC=C12.N1CCCCC1.N1CCCC1 Chemical compound C1NCCC2=CC=CC=C12.N1CCCCC1.N1CCCC1 UNNHOBJPTGBVJQ-UHFFFAOYSA-N 0.000 claims description 2
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 claims description 2
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960002591 hydroxyproline Drugs 0.000 claims description 2
- VWHRYODZTDMVSS-QMMMGPOBSA-N m-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(F)=C1 VWHRYODZTDMVSS-QMMMGPOBSA-N 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229940030966 pyrrole Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 101800004538 Bradykinin Proteins 0.000 abstract description 6
- 238000010647 peptide synthesis reaction Methods 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 125000001589 carboacyl group Chemical group 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 142
- 239000011347 resin Substances 0.000 description 32
- 229920005989 resin Polymers 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 14
- 150000003862 amino acid derivatives Chemical class 0.000 description 14
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000005859 coupling reaction Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 3
- GOUUPUICWUFXPM-XIKOKIGWSA-N (2s,4r)-1-(9h-fluoren-9-ylmethoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 GOUUPUICWUFXPM-XIKOKIGWSA-N 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- SNZIFNXFAFKRKT-NSHDSACASA-N (2s)-2-azaniumyl-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoate Chemical compound CC(C)(C)OC1=CC=C(C[C@H]([NH3+])C([O-])=O)C=C1 SNZIFNXFAFKRKT-NSHDSACASA-N 0.000 description 1
- MXWMFBYWXMXRPD-YFKPBYRVSA-N (2s)-2-azaniumyl-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoate Chemical compound CC(C)(C)OC(=O)C[C@H](N)C(O)=O MXWMFBYWXMXRPD-YFKPBYRVSA-N 0.000 description 1
- QTWZCODKTSUZJN-LJAQVGFWSA-N (2s)-5-[[amino-[(2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C(C(C)=C1C)=C(C)C2=C1OC(C)(C)CC2 QTWZCODKTSUZJN-LJAQVGFWSA-N 0.000 description 1
- IZKGGDFLLNVXNZ-KRWDZBQOSA-N (2s)-5-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 IZKGGDFLLNVXNZ-KRWDZBQOSA-N 0.000 description 1
- JBZXLQHJZHITMW-RXYZOABWSA-N (2s,3as,7as)-1-(9h-fluoren-9-ylmethoxycarbonyl)-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O JBZXLQHJZHITMW-RXYZOABWSA-N 0.000 description 1
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical compound C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 description 1
- LXUNZSDDXMPKLP-UHFFFAOYSA-N 2-Methylbenzenethiol Chemical compound CC1=CC=CC=C1S LXUNZSDDXMPKLP-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical compound C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 241001071944 Cyta Species 0.000 description 1
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- VGALFAWDSNRXJK-VIFPVBQESA-N L-aspartic acid beta-benzyl ester Chemical compound OC(=O)[C@@H](N)CC(=O)OCC1=CC=CC=C1 VGALFAWDSNRXJK-VIFPVBQESA-N 0.000 description 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- KAFHLONDOVSENM-HNNXBMFYSA-N O-Benzyl-L-tyrosine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OCC1=CC=CC=C1 KAFHLONDOVSENM-HNNXBMFYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- MSWIFFGHKBTPMY-VFUQPONKSA-L magnesium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O MSWIFFGHKBTPMY-VFUQPONKSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- JLKXXDAJGKKSNK-UHFFFAOYSA-N perchloric acid;pyridine Chemical compound OCl(=O)(=O)=O.C1=CC=NC=C1 JLKXXDAJGKKSNK-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- ZJOSXOOPEBJBMC-LJRWBPDUSA-N pseudaminic acid Chemical compound CC(=O)N[C@@H]([C@@H](O)C)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@@H]1NC(C)=O ZJOSXOOPEBJBMC-LJRWBPDUSA-N 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 125000003156 secondary amide group Chemical group 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- ZERULLAPCVRMCO-UHFFFAOYSA-N sulfure de di n-propyle Natural products CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Peptides of the formula I A-B-C-E-F-K-(D)-Tic-G-M-F'-I (I> in which A is hydrogen, alkyl, alkanoyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, aryl, arylsulphonyl, heteroaryl or an amino acid, each of which can optionally be substituted, B is a basic amino acid, C is a di- or tripeptide, E is the residue of an aromatic amino acid, F is, independently of one another, an amino acid which is optionally substituted in the side chain or is a direct bond, G is an amino acid, F' is defined as F, can be -NH-(CH2)2-8 or optionally a direct bond, I is -OH, -NH2 or -NHC2H5 and K is a radical -NH(CH2)-1-4-CO- or is a direct bond, have bradykinin-antagonistic action. Their therapeutic uses comprise all pathological states which are promoted, induced or sustained by bradykinin and bradykinin- related peptides. The peptides of the formula I are prepared by known methods of peptide synthesis.
Description
COMMONWEALTH OF AUSTRALIA Form PATENTS ACT 1952-69 COMPLETE SPECIFICATION (ORIGINAL) 6104 Class lnt. Class Application Number: Lodged: Complete Specification Lodged: Velated Art: Accepted: Published: Name of Applicant: HOECHST
AKTIENGESELLSCHAFT'
Address of Applicant: 50 Bruningstrasse, D-6230 Frankfurt/Main Federal Republic of Germany Actual Inventor: Address for Service: STEPHEN HENKE, HIRISTO ANAGNOSTOPULOS, GERHARD BREIPOHL, JOCHEN KNOLLE JENS STECHL and BEPNWAPD SCHOLKENS )M*TQWAW1WW teRWatrrark Patent Trademark Attorneys 50 QUEEN STREET, MELBOURNE, AUSTRALIA, 3000.
Ccrmplete Specification for the invention entitled: PEPTIDES HAVING BRADYKININ ANTAGONIST ACTION The following statement is a full description of this invention, including the best method of performing it known to Us I HOECHST AKTIENGESELLSCHAFT HOE 88/F 328K Dr.MY/gm Description Peptides having bradykinin antagonist action The invention relates to novel peptides having bradykinin antagonist action and to a process for their preparation.
Bradykinin antagonist peptides are described in WO 86/07263 in which, inter alia, L-Pro in position 7 of the peptide hormone bradykinin or other bradykinin analogs is replaced by a D-amino acid, such as D-Phe, D-Thi, D-Pal, CDF, D-Nal, MDY, D-Phg, D-His, D-Trp, D-Tyr, D-hPhe, D-Val, D-Ala, D-His, D-Ile, D-Leu and 0 0« DOMT.
0 0 0 The invention is based on the object of finding novel o. active peptides having bradykinin antagonist action.
This object is achieved by the peptides of the formula I A-B-C-E-F-K-(D)-Tic-G-M-F'-I in which A denotes hydrogen, -alkyl, a (Ci-C,)-alkanoyl, (Ci-Cs)-alkoxycarbonyl or (Ci-C) -alkylsulfonyl, in which in each case 1, 2 or 3 hydrogen atoms are optionally replaced by 1, 2 or 3 identical or different radicals from the series comprising carboxyl, amino,
(C
1 -alkyl, (Ci-C 4 -alkylamino, hydroxyl,
(C
1
-C
4 -alkoxy, halogen, di-(C 1 -alkylamino, -2carbamoyl, sulfamoyl, (Cl-CA) -alkoxycarbonyl,
(C
6
_C,
2 -aryl and
(C
6
-C
1 2 )-aryl-(C 1
C
5 )-alkyl, or in which in each case I hydrogen atom is optionally replaced by a radical from the series comprising
(C
3 -cycloalkyl,
(C
1
-C
4 -alkylsulf onyl,
(C
1
-C
4 -alkylsulf inyl,
(C,-C
1 2 -aryl- (Cl-CA) -alkylsulf onyl, 1 2 -aryl- (C1-C4) -alkylsulf inyl,
(C
6
-C
12 -aryloxy, 000:(C 3
-C
9 -heteroaryl and 25.(C 3
-C
9 -heteroaryloxy and or 2 hydrogen atoms are replaced by 1 or 2 identical or different radicals from the series comprising carboxyl, amino, (Cl-C 4 -alkylainino, hydroxyl, 0 (Cl-C) -alkoxy, 04 halogen, 25 di- (C 1
-C
4 -alkyl amino, j 005 0carbamoyl, sulfamoyl, -alkoxycarbonyl,
(C
6
-C
1 2 -aryl and 2 -aryl- (C 1
-C
5 -alkyl, a 2 denotes (C 3 -C)-cycloalkyl, carbamroyl, which may be optionally substituted on the nitrogen by (Cl-C 6 )-alkyl or (C 6
-C
1 2 )-aryl,
(C
6
-C
1 2 -aryl (C7-C 13 -aryloyl,
(C
6
-C
12 -arylsulf onyl,
(C
3
-C
9 -heteroaryl, or (C 3
-C
9 -heteroaryloyl, where in the radicals defined under and a 2 in each case aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl is optionally substituted by 1, 2, 3 or 4 identical or different radicals from the series comnpris ing carboxyl, amino, nitro, (Cl-C 4 -alkylanino, hydro xyl, (Cl-C 4 -alkyl, (Cl-C) -alkoxy, halogen, cyano, di- (Cl-C 4 -alkylaxnino, carbainoyl, sulfamoyl and -alkoxycarbonyl, or 4, a 3 denotes a radical of the formula II 4, ~R 1 N CH C -(I R is def ined as A under or a 2 R ~2 deoehyrgnomeyl R denotes hydrogen ormehl (Cl-C 6 -alkyl, preferably (Cl-C 4 -alkyl, 4, 4, which is optionally ionosubstituted by amino, 425 substituted amino, hydroxyl, carboxyl, 4, 4,carbamoyl, 00 guanidino, substituted guanidino, ureido, mercapto, methylmercapto, phenyl, 4-chiorophenyl, 4-f luorophenyl, 4 -nitrophenyl, 4 -methoxyphenyl, 1II1Baru-- S.
I
4 4-hydroxyphenyl, phthalimido, 4-imidazolyl, 3-indolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl or cyclohexyl, where substituted amino stands for a compound -NH-A- and substituted guanidino stands for a compound -NH-C(NH)-NH-A, in which A is defined as under or a 2 B stands for a basic amino acid in the L- or D-con- 0 figuration, which may be substituted in the side chain; C stands for a compound of the formula IIIa or IIIb :G'-G'-Gly
G'-NH-(CH
2 n
-CO
S* (Ilia) (IIIb) in which G' independently of one anotherdenotes a radical of S00the formula IV S*
R
4
R
5 0 I I II N CH C (IV) in which R and R 5 together with the atoms carrying them form a heterocyclic mono-, bi- or tricyclic ring system having 12 to 15 carbon atoms, and n is 2 to 8; E stands for the radical of an aromatic amino acid; F independently of one another denotes the radical of a neutral, acidic or basic, aliphatic or aromatic amino acid which may be substituted in the side chain, or stands for a direct bond; (D)-Tic denotes the radical of the formula V
HO
G(V)
G is as defined above for G' or denotes a direct bond; F' is as defined for F, denotes a radical with n 2 to 8, or, if G does not denote a direct bond, can stand for a direct bond, and I is -OH, -NH or -NHC 2
H.,
K denotes the radical -NH-(Cfl 2 with x 1-4 or stands for a direct bond, and 14 is as defined for F, and their physiologically tolerable salts.
If not stated otherwise, the abbreviation of an amino acid radical without a stereodescriptor stands for the radical in the L-form. (compare Schr~5der, Liibke; The Peptides, Volume I, New York 1965, pages XXII-XXIII; o Houben-Weyl, Methoden der Organischen Chemie (Methods of organic Chemistry), Volume XV/l and 2, Stuttgart 1974), such as, for example, Aad, Abu, TAbu, ABz, 2ABz, eAca, Ach, Acp, Adpd, Ahb, Aib, AAib, Ala, Aia, Aila, Aig, All, Ama, Amt, Ape, Apm, Apr, Arg, Asn, Asp, Asu, Aze, Azi, Bai, Bph, Can, Cit, Cys, Cyta, Daad, Dab, Dadd, Dap, Dapn, Dasu,, Djen, Dpa, Dtc, 0400 Fel, Gin, Glu, Gly, Guy, hLAia, hArg, hCys, hGln, hGiu, His, hule, hLeu, hLys, h~et, hPhe, hPro, hSer, hmhr, hTrp, hTyr,J Hyl, Hyp, 3Hyp, Ile, Ise, Iva, Kyn, Lant, Lcn, Leu, Lsg, 0 Lys, ALys, &Lys, Met, Mim, Min, nArg, Nie, Nva, Oly, Orn, Pan, Pec, Pen, Phe, Phg, Pic, Pro, Pro, Pse, Pya, Pyr, Pza, Qin, Ros, Sar, Sec, Sem, Ser, Thi, AThi, Thr, Thy, 0 0 Thx, Tia, Tle, Tiy, Trp, Trta, Tyr, Val.
Suitable radicals of a heterocyclic ring systeLI of the formula IV are in particular radicals of heterocycles of the group below: Pyrrolidine~ piperidine tetrahydroisoquinoline decahydroisoquinoline octahydroindole octahydrocyclopenta[b~pyrroie 2-aza-bicyclo(2.2.2]octane 2-azabicyclot2.2.llheptane 2-azaspiro- 2-azaspiro[4.4]nonane spiro[(bi- -6 cyclu[2.2.l]heptane)-2,3-pyrrolidine) spiro[(bicyclo[2.2 .2 ]octane) -2,3-pyrrolidine] 2-azatricyclo- [4.3.O.16' 9 ]decane decahydrocyclohepta~b]pyrrole octahydroisoindole octahydrocyclopenta~c]pyrrole 2,3,3a,4,5,7a-hexahydroindole tetrahydrothiazole 2-azabicyclo[3.1.O]hexane isoxazolidine pyrazolidine hydroxyproline all of which may be optionally substituted.
00 0 0 *0 0
A
04 00 0@ 0 I I -7 C>-o
N
A
Co OC:7*Nco-
SA
co-
N-
~e Si, S S @1 1,5 iS S 5*45 $054 s5* 44 '5 4 4, Si S
I
45#*
S@
44 4 55 0 ii 0* S .0 54 .544 S .05 *4 4 (4co-
I
Co
M
NCo-o
F>
0 co-
'IN
T
8 The heterocycles based on the abovementioned radicals are known, for example, from US-A-4,344,949, US-A-4,374,847, US-A-4,350,704, EP-A-50,800, EP-A-31,741, EP-A-51,020, EP-A-49,658, EP-A-49,605, EP-A-29,488, EP-A-46,953, EP-A-52,870, EP-A-271,865, DE-A-3,226,768, DE-A-3 '51,690, DE-A-3,210,496, DE-A-3,211,397, DE-A-3,211,676, DE-A-3,227,055, DE-A-3,242,151, DE-A-3,246,503 and DE-A-3,246,757.
Some of these heterocycles are furthermore proposed in DE-A-3,818,850.3.
If not stated otherwise in the individual case, alkyl can be straight-chain or branched. The same applies to radicals derived therefrom such as alkoxy, aralkyl or 15 alkanoyl.
(C
6
-C
12 )-Aryl preferably denotes phenyl, naphthyl or biphenylyl. Radicals derived therefrom, such as aryloxy, aralkyl or aroyl, are to be formulated correspondingly.
Halo stands for fluorine, chlorine, bromine or iodine, preferably for chlorine.
Possible salts are, in particular, alkali metal or alkaline earth metal salts, salts with physiologically S* tolerable amines and salts with inorganic or organic acids such as, for example, HC1, HBr, H 2 SO,, H 3
PO
4 maleic acid, fumaric acid, citric acid, tartaric acid and acetic acid.
Preferred peptides of the formula I are those in which B denotes Arg, Lys, Orn, 2 ,4-diaminobutyroyl or an Lhomoarginine radical, where in each case the amino or guanidino group of the side chain may be substituted by A as described under or a 2 *1
I_
-9- E stands for the radical of an aromatic amino acid in the L- or D-configuration, which contains 6 to 14 carbon atoms in the aryl moiety as ring members, such as phenylalanine which is optionally substituted by halogen in the 3- or 4-position, tyrosine, O-methyltyrosine, 2-thienylalanine, 2pyridylalanine or naphthylalanine; F' denotes the radical of a basic amino acid in the Lor D-configuration, such as Arg or Lys, where the guanidino group or amino group of the side chain may be replaced by A as described under or a 2 or denotes a radical with n 2 to 8 and K stands for the radical with x 2-4 or denotes a direct bond.
Particularly preferred peptides of the formula I are those in which B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain is unsubstituted or may be substituted by (Cl-C,)-alkanoyl, (C7- 0 C 13 )-aryloyl, (C-C 9 -heteroaryloyl, (C 1
-C
8 -alkylsulfonyl or (C 6
-C
1 )-arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl .4 radicals may optionally be substituted, as described under a 2 with 1, 2, 3 or 4 identical or different radicals.
E denotes phenylalanine, 2-chlorophenylalanine, 3-chlorophenylalanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, tyrosine, 0-methyltyrosine or 0-(2-thienyl)alanine; K stands for a direct bond and M stands for a direct bond 10 Very particularly preferred peptides of the formula I are those in which A denotes hydrogen, or (L)-H-Arg, or Lys or or (L)-H-Orn, B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain may be substituted by hydrogen, (C 1
-C
8 )-alkanoyl, (C,-C 1 aryloyl, (C 3
-C
9 )-heteroaryloyl, (C 1 -alkylsulfonyl or (C.-C 12 )-arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted with 1, 2, 3 or 4 identical or different radicals from the series comprising methyl, methoxy and halogen.
C
C denotes Pro-Pro-Gly, Hyp-Pro-Gly or Pro-Hyp-Gly E denotes Phe or Thia F denotes Ser, Hser, Lys, Leu, Val, Nle, Ile or Thr K stands for a direct bond M stands for a direct bond G stands for the radical of a heterocyclic ring system 2 of the formula IV, where the radicals of the heterocycles pyrrolidine piperidine tetrahydroisoquinoline cis- and trans-decahydroisoquinoline cis-endo-octahydroindole cis-exooctahydroindole trans-octahydroindole cisendo-, cis-exo-, trans-octahydrocyclopentano[b]pyrrole, or hydroxyproline are preferred.
F' denote Arg and I stands for OH.
Examples of very particularly preferred peptides of the 1
A
-I
u II 11 formula I are: H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH H-(D)-Arg-Arg-Prq-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH H-(D)-Arg-Arg-Pro-Hyp-Gly- Phe-Ser-(D)-Tic-Oic-Arg-OH H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH H-(D)-Arg-Arg-Pro-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH The invention furthermore relates to a process for the preparation of peptides of the formula I, which comprises a) reacting a fragment having a C-terminal free carboxyl group or its activated derivative with an 4 appropriate fragment having an N-terminal free amino group or o 0 b) synthesizing the peptide stepwise, optionally o splitting off one or more protective groups temp- *0*15 orarily introduced for the protection of other functions in the compound obtained according to (a) or and optionally converting the compounds of the formula I thus obtained into their physiologically tolerable salt.
o 0 The peptides of the present invention were prepared by generally known methods of peptide chemistry, see, for example, Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Volume 15/2, preferably by means of solid phase synthesis such as described, for example, by B. Merrifield, J.Am.Chem.Soc. 85, 2149 (1963) or R. C. Sheppard, Int. J. Peptide Protein Res. 21, 118 (1983) or by equivalent known methods. Urethane protective groups such as, for example, the tert-butyloxycarbonyl(Boc) or fluorenylmethoxycarbonyl(Fmoc) protective group are used as a-amino protective group. If necessary for the prevention of side reactions or for the synthesis of specific peptides, the functional groups in the side chain of amino acids are additionally protected by suitable protective groups (see, for example, T.W.
Greene, "Protective Groups in Organic Synthesis"), where iiii~ 12 primarily, Arg(Tos), Arg(Mts), Arg(Mtr), Arg(PMC), Asp(OBzl), Asp(OBut), Cys(4-MeBzl), Cys(Acm), Cys(SBut), Glu(OBzl), Glu(OBut), His(Tos), His(Fmoc), His(Dnp), His(Trt), Lys(Cl-Z), Lys(Boc), Met(O), Ser(Bzl), Ser(But), Thr- (Bzl), Thr(But), Trp(Mts), Trp(CHO), Tyr(Br-Z), Tyr(Bzl) or Tyr(But) are employed.
Solid phase synthesis begins at the C-terminal end of the peptide with the coupling of a protected amino acid to an appropriate resin. Starting materials of this type may be obtained by linking a protected amino acid via an ester or amide bond to a polystyrene or polyacrylamide resin modified with a chloromethyl, hydroxymethyl, benzhydrylamino(BHA) or methylbenzhydrylamino(MBHA) group. The 5 resins used as support materials are commercially obtaino0 0 able. BHA and MBHA resins are usually used if the peptide So synthesized is intended to have a free amide group at the C-terminus. If the peptide is intended to have a secondary amide group at the C-terminal end, a chloromethyl or hydroxymethyl resin is used and the splitting off is carried out using the corresponding amines. If it is a 4.
0 wished to obtain, for example, the ethylamide, the peptide can be split off from the resin using ethylamine, the splitting off of the side chain protective groups subsequently being carried out by means of other suitable reagents. If it is intended to retain the tert-butyl protective groups of the amino acid side chain in the peptide, the synthesis is carried out using the Fmoc protective group for temporary blocking of the a-amino group of the amino acid using the method described, for example, in R.C. Sheppard, J.Chem.Soc., Chem.Comm 1982, 587, the guanidino function of the arginine being protected by protonation with pyridinium perchlorate and the protection of the other functionalized amino acids in the side chain being carried out using benzyl protective groups which can be split off by means of catalytic transfer hydrogenation Felix et al. J. Org. Chem. 13, 4194 (1978) or by means of sodium in liquid ammonia -13 Roberts, J.Am.Chem.Soc. 76, 6203 (1954)).
SAfter splitting off the amino protective group of the amino acid coupled to the resin using a suitable reagent, such as, for example, trifluoroacetic acid in methylene chloride in the case of the Boc protective group or a strength solution of piperidine in dimethylformamide in the case of the Fmoc protective group, the subsequently protected amino acids are successively coupled in the desired sequence. The intermediately resulting N-terminal protected peptide resins are deblocked by means of the reagents described above before linkage with the subsequent amino acid derivative.
41444 All possible activating reagents used in peptide synt .o thesis can be used as coupling reagents, see, for ex- 15 ample, Houben-Weyl, Methoden der organischen Chemie S (Methods of Organic Chemistry), Volume 15/2, in particular, however, carbodiimides such as, for example, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropyl-carbodiimide or N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.
The coupling can in this case be carried out directly by addition of amino acid derivative and the activating reagent and, if desired, a racemization-suppressing additive such as, for example, 1-hydroxy-benzotriazole .4 (HOBt) K6nig, R. Geiger, Chem. Ber. 103, 708 (1970)) or 3-hydroxy-4-oxo-3,4-dihydrobenzo-triazine (HOObt) K6nig, R. Geiger, Chem.Ber. 103, 2054 (1970)) to the resin or, however, the preactivation of the amino acid derivative as symmetrical anhydride or HOBt or HOObt ester can be carried out separately and the solution of the activated species in a suitable solvent can be added to the peptide resin capable of coupling.
The coupling or activation of the amino acid derivative with one of the abovementioned activating reagents can be carried out in dimethylformamide, N-methylpyrrolidone or methylene chloride or a mixture of the solvents mentioned. The activated amino acid derivative is L: 1 a i i ir 14 customarily employed in a 1.5 to 4 fold excess. In cases in which an incomplete coupling takes place, the coupling reaction is repeated without previously carrying out the deblocking of the a-amino group of the peptide resin necessary for the coupling of the following amino acid.
The successful course of the coupling reaction can be monitored by means of the ninhydrin reaction, such as described, for example, by E. Kaiser et al. Anal.
Biochem. 34 595 (1970). The synthesis can also be auto- 10 mated, for example using a peptide synthesizer model 430A from Applied Biosystems, it being possible either to use the synthesis program provided by the apparatus manufacturer or else, however, one set up by the user himself.
The latter are in particular employed in the use of amino acid derivatives protected with the Fmoc group.
*9 I *O 9 99 9 901 9* .9 After synthesis of the peptides in the previously des- S cribed manner, the peptide can be split off from the resin using reagents, such as, for example, liquid hydrogen fluoride (preferably in the peptides prepared according to the Boc method) or trifluoroacetic acid (preferably in the peptides synthesized according to the Fmoc method). These reagents not only cleave the peptide from the resin but also the other side chain protective ,o groups of the amino acid derivative. In this manner, the peptide is obtained in the form of the free acid in addition using BHA and MBHA resins. With the BHA or MBHA S resins, the peptide is obtained as acid amide when splitting off is carried out using hydrogen fluoride or trifluoromethanesulfonic acid. Additional processes for the preparation of peptide amides are described in German Patent Applications P 37 11 866.8 and P 37 43 620.1. The splitting off of the peptide amides from the resin here is carried out by treatment with medium strength acids (for example trifluoroacetic acid) usually used in peptide synthesis, cation entrainer substances such as phenol, cresol, thiocresol, anisole, thioanisole, ethanedithiol, dimethyl sulfide, ethyl methyl sulfide or 9 I a0
__J
similar cation entrainers customary in solid phase synthesis being added individually or as a mixture of two or more of these auxiliaries. In this case, the trifluoroacetic acid can also be used diluted by suitable solvents, such as, for example, methylene chloride.
If the tert-butyl or benzyl side chain protective groups of the peptides are to be retained, the splitting off of the peptide synthesized on a particularly modified support resin is carried out using 1% trifluoroacetic acid in methylene chloride, such as described, for example, in R.C. Sheppard J.Chem. Soc., Chem. Comm. 1982, 587. If individual tert-butyl or benzyl side chain protective groups are to be retained, a suitable combination of synthesis and splitting off methods is used.
a," For the synthesis of peptides having a C-terminal amide "2 e grouping or an w-amino or w-guanidinoalkyl grouping, the modified support resin described by Sheppard is likewise used. After the synthesis, the peptide fully protected in the side chain is split off from the resin and subseo; quently reacted with the appropriate amine or w-aminoalkylamine or w-guanidinoalkylamine in classical solution synthesis, it being possible for optionally present o* additional functional groups to be temporarily protected in a known manner.
An additional process for the preparation of peptides having an w-aminoalkyl grouping is described in German Patent Application P 36 35 670.0.
The peptides of the present invention were preferably synthesized by two general protective group tactics using the solid phase technique: The synthesis was carried out using an automatic peptide synthesizer :odel 430 A from Applied Biosystems, with Boc or Fmoc protective groups for temporary blockage of .ne i -16- a-amino group.
When using the Boc protective group, the synthesis cycles pre-programmed by the manufacturer of the apparatus were used for the synthesis.
The synthesis of the peptides having a free carboxyl group on the C-terminal end was carried out on a 4- (hydroxymethyl)phenylacetamidomethylpolystyrene resin functionalized with the corresponding Boc amino acid Merrifield, J. Org. Chem. 43, 2845 (1978)) from Applied Biosystems. An MBHA resin from the same firm was used for the preparation of the peptide amides.
0 N,N'-DicyclohexylcarbodiimideorN,N'-diisopropylcarbodio o imide were used as activating reagents. Activation was carried out as the symmetrical anhydride, as the HOBt o.1S ester or HOObt ester in CH 2 C1 2
CH
2 Cl 2 D1F mixtures or o NMP. 2-4 equivalents of activated amino acid derivative were employed for the coupling. In cases in which the coupling took place incompletely, the reaction was repeated.
*4 o 0 02'0. During the use of the Fmoc protective group for the temporary protection of the a-amino group, our own '0o synthesis programs were used for synthesis using the automatic peptide synthesizer model 430A from Applied Biosystems. The synthesis was carried out on a p-benzyloxybenzyl alcohol resin Wang, J.Am.Chem.Soc. 1328 (1973)) from Bachem which was esterified by a known method Atherton et al. J.C.S. Chem. Comm. 1981, 336) using the appropriate amino acid. The activation of the amino acid derivatives as HOBt or HOObt esters was carried out directly in the amino acid cartridges provided by the apparatus manufacturer by addition of a solution of diisopropylcarbodiimide in DMF to the previously weighed-in mixture of amino acid derivative and HOBt or HOObt. Fmoc-amino acid-OObt esters prepared in substance can likewise be employed as described in European Patent Application 87,107,634.5. The splitting 1: 1. -17 off of the Fmoc protective group was carried out using a strength solution of piperidine in DMF in the reaction vessel. The excess of reactive amino acid derivative used was 1.5 to 2.5 equivalents. If the coupling was not complete, it was repeated as in the Boc method.
The peptides according to the invention have, individually or in combination, a bradykinin antagonist action which can be tested in various models (see Handbook of Exp. Pharmacol. Vol. 25, Springer Verlag, 1970, p. 53for example on the isolated rat uterus, on the guinea pig ileum or on the isolated pulmonary artery of the guinea pig.
a a For testing the peptides according to the invention on the isolated arteria pulmonalis, guinea pigs (Dunkin S° Hartley) having a weight of 400 450 g are sacrificed S° by a blow to the back of the neck.
The thorax is opened and the arteria pulmonalis is 6 carefully dissected out. The surrounding tissue is 20 carefully removed and the arteria pulmonalis is cut o spirally at an angle of 450.
o° The vessel strip of 2.5 cm length and 3-4 mm width is fixed in a 10 ml capacity organ bath which is filled with Ringer solution.
Composition of the solution in mmol/l NaCl 154 KC1 5.6 CaC 2 l 1.9 NaHCO 3 2.4 Glucose 02 and 5% CO 2 is bubbled through the solution, which is warmed to 37 0 C. The pH is 7.4 and the preload on the vessel strip is 1.0 g.
18 The isotonic contraction changes are detected using a lever arrangement and an HF modem (position sensor) from Hugo Sachs and recorded on a compensating recorder (BEC, A Goerz Metrawatt SE 460).
After equilibration for 1 hour, the experiment is begun.
After the vessel strips have achieved their maximum sensitivity to 2 x 10-7 mol/l of bradykinin bradykinin leads to a contraction of the vessel strips the peptides are allowed to act for 10 minutes in each case in the doses 5 x 10-'3 1 x 10-5 mol/l and, after adding bradykinin again, the decrease in the effect of bradykinin as opposed to the control is compared.
e :4 For the detection of a partial agonistic effect, the peptides are used in the doses 1 x 10-5 I X 10-3 mol/l.
The IC 50 values of the peptides according to the invention calculated from the dose-effect curves are shown in Table 1.
Table 1: Compound
IC
50
[M]
H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH 4,6 10-6 H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Thia-Arg-OH 2,1 10-6 H-CL Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH 1,2 10-5 H-(D)-Arg-Arg-Hyp.Pro-Gly-Phe-Glo-(D)-Tic-Phe-Arg-OH 2,4 H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-7iic-Phe-Arg(Mtr)-OH 2,5 105 H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-TicPro-Arg-OH 2,5 10-7 H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-ProArgH 1, H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH 5,6 10-8 H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-O-Ala-(D)-Tic-Aoc-ArgOH 1,7 10-6 H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-Gly-(D)-Tic-Aoc-Arg-OH 3,9 107 H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Gly-(D)-Tic-(D,L)-Oic-Arg-OH 3,2 107 H-(D)-Arg-(D-Arg-Hyp-ro-GlyThia-Ser-(D 4,8 10-7 H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Tic-Arg-OH 1,7 10-7 19 Compound IC 50
[M]
H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-0H 1,1 10-8 H-(0)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-0H 4,6 108 H-(D)-Tyr-Arg-Pro-Hyp-Gy-Thia-Ser-()-Tic-Aoc-Arg-H 6,2 10-8 H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-(D)-Dic-Arg-0H 2,6 10-5 H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH 5,4 H-(D)-Arg-Lys-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH 3,2 10-7 H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH 6,8 10-9 H-(D)-Arg-Arg-(NO2)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH 6,4 10-8 H-(D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Dic-Arg-OH 4,2 3,4 10-7 H-Arg-(Tos)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Dic-Arg-OH 3,0 10-8 #H-Arg-(Tos)-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Dic-Arg-0H 1,8 10-8 The therapeutic utility of the peptides according to the 15 invention includes all pathological states which are ,o mediated, caused or supported by bradykinin and brady- 0 0 a kinin-related peptides. This includes, inter alia, traumas, such as wounds, burns, rashes, erythemas, edemas, angina, arthritis, asthma, allergies, rhinitis, shock, inflammations, low blood pressure, pain, itching and changed sperm motility.
The invention therefore also relates to the use of peptides of the formula I as medicaments, and to pharmaceutical preparations which contain these compounds.
5 Pharmaceutical preparations contain an effective amount of the active substance of the formula I individually or in combination together with an inorganic or organic pharmaceutically utilizable excipient.
Administration can be carried out enterally, parenterally such as, for example, subcutaneously, i.m. or i.v. sublingually, epicutaneously, nasally, rectally, intravaginally, intrabuccally or by inhalation. The dosage of the active substance depends on the mammal species, the body weight, age and on the manner of administration.
The pharmaceutical preparations of the present invention are prepared in solution, mixing, granulating or tablet coating processes known per se.
For oral administration or application to the mucosa, the active compounds are mixed with the customary additives for this, such as excipients, stabilizers or inert diluents, and brought into suitable forms for administration, such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily suspensions or aqueous, alcoholic or oily solutions, by customary methods. Inert excipients which may be used are, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose, magnesium stearyl fumarate or starch, in particular maize starch. In this case, the preparation may be present both as dry and moist granules. Suitable oily excipients or solvents are, for example, vegetable or animal oils, such as sunflower oil and cod liver oil.
a ae a A preparation for topical application may be present as 0 an aqueous or oily solution, lotion, emulsion or gel, ointment or fatty ointment or, if possible, in spray a form, it being possible to improve the adhesion, if desired, by addition of a polymer.
S For the intranasal form of administration, the compounds j 2'5 are mixed with the customary auxiliaries for this, such as stabilizers or inert diluents, and brought into suit- SI, able forms for administration, such as aqueous, alcoholic or oily suspensions or aqueous, alcoholic or oily solutions, by customary methods. Chelating agents, ethylenediamine-N,N,N',N'-tetraacetic acid, citric acid, S tartaric acid or their salts may be added to aqueous intranasal preparations. Administration of the nasal solutions can be carried out by means of metered atomizers or as nasal drops, having a viscosity-increasing component, or nasal gels or nasal creams.
F
-21- For administration by inhalation, atomizers or pressurized gas packs using inert carrier gases can be used.
For intravenous, subcutaneous, epicutaneous or intradermal administration, the active compounds or their physiologically tolerable salts, if desired with the pharmaceutically customary auxiliaries, for example for isotonisizing or adjusting pH, and solubilizers, emulsifiers or other auxiliaries, are brought into solution, suspension or emulsion.
Because of the short half-lives of some of the medicaments described in body fluids, the use of injectable sustained release preparations is efficient. Medicament forms which may be used are, for example, oily crystal suspensions, microcapsules, rods or implants, it being possible to synthesize the latter from tissue-compatible polymers, in particular biodegradable polymers, such as, o 0 for example, those based on polylactic acid/ polyglycolic acid copolymers or human albumin.
9. '2 A suitable dose range for forms for topical application and administration by inhalation are solutions containing 0.01-5 mg/ml, and with forms for systemic administration 0.01-10 mg/kg is suitable.
List of abbreviations: The abbreviations used for amino acids correspond to the as three-letter code customary in peptide chemistry as described in Europ. J. Biochem. 138, 9 (1984). Additionally used abbreviations are listed below.
0440 Acm Acetamidomethyl e-Ahx e-Aminohexanoyl Aoc cis, endo-2-Azabicyclo[3.3.0]octane-3-Scarbonyl Boc tert-Butyloxycarbonyl But tert-Butyl 22 Bzl c1-z
DMF
Dnp Fmoc Me 4 -Mebzl Mtr Mts
NMP
Oic Opr PmC
TFA
Tcs Thi a Tic Trt Benzyl 4 -Chlorobenzyloxycarbonyl Dimethyl formainide 2, 4-Dinitrophenyl 9 -Fluorenylmethoxycarbonyl Methyl 4-Methylbenzyl 4-Methoxy-2 6-trimethylphenylsulfonyl Mesitylene-2-sulfonyl N-Methylpyrrol idine cis -endo-octahydroindol-2 -ylcarbonyl Isoxazolidi-n-3-ylcarbonyl 2,2,5,7, 8-Pentaiethylchroman-6-sulfonyl Trifluoroacetic aciLd 4 -Methyiphenylsul fonyl 2 -Thienylalanyl 1,2,3, 4-Tetrahydroisoquinolin-3-ylcarbonyl Trityl 0*CCCI
WA
90 0 0 o I. Ct 0 00* o o a 00 00 99 9 9 The following examples are intended to illustrate the preferred methods for solid phase synthesis of the peptides according to the invention, without limiting the invention thereto.
The amino acid derivatives below were used: *09 *9 I I I I
II
Fmoc-Arg(Mtr)-OH, Boc-(D)-Arg-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Hyp-OH, Fmoc-Pro-OObt, Fmoc-Gly-OObt, Fmoc-Phe-CiObt, 9 Fmoc-Ser(tBu)-O0bt, Fmoc- (D)-Tic-OH, Fmoc-Gln-OH, Fmoc-Aoc-OH, Fmoc-Thia-OH, Frnoc-Opr-OH, Fmoc- (D)-Asn-OH, t Fmoc-A-Ala-OH, Fmoc-Oic-OH.
Example 1: 13 Q H- -Arg-Arg-Hyp-Pro-Gly-Phe-Ser- -Tic-Phe-Arg-OH was synthesized stepwise using a peptide synthesizer model 430 A from Applied Biosystems by the Fmoc method on a p-benzyloxybenzyl alcohol resin from Novabiochem (loading about 0.5 mmhol/g of resin) esterified with Fmoc- Arg(Mtr)-OH. 1 g of the resin was employed and the ,I I a,,carsmreBha~ 23 synthesis was carried out with the aid of a synthesis program modified for the Fmoc method.
In each case 1 mmol of the amino acid derivative having a free carboxyl group together with 0.95 mmol of HOObt was weighed into the cartridges of the synthesizer. The I preactivation of these amino acids was carried out directly in the cartridges by dissolving in 4 ml of DMF and adding 2 ml of a 0.55 mol solution of diisopropylcarbodiimide in DMF.
The HOObt esters of the other amino acids were dissolved in 6 ml of NMP and then similarly coupled to the resin previously deblocked using 20% piperidine in DMF, like the amino acids preactivated in situ. After completion of the synthesis, the peptide was split off from the resin using thioanisole and ethanedithiol as cation entrainers, with simultaneous removal of the side chain protective groups using trifluoroacetic acid. The residue obtained after stripping off the trifluoroacetic acid was repeatedly digested with ethyl acetate and centrifuged. The residue which remained was chromatographed on ®Sephadex LH 20 using 10% strength acetic acid. The fractions S containing the pure peptide were combined and freezedried.
o :25 4 4 a o o 4r 44 a 4 44 iu a a 484« a o ft a a MS(FAB) 1294 (M+H) The peptides of Examples 2 to 24 below were prepared and purified analogously to Example 1.
Example 2: H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-(D)-Ser-(D)-Tic-Phe-Arg-OH MS(FAB) 1294 (M+H) Example 3: H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Thia-Arg-OH MS(FAB) 1306 (M+H) -24- Example 4: H- -Arg-Arg-Pro-Hyp-Gly-Phe- Ser- (D)-Tic-Phe-Arg-
OH
MS(FAB) :1294 (M+H) Example H- -Arg- Arg- Hyp- Pro- Gly- The- Gin- The- Arg- OH MS(FAB) :1335 (M+H) Example 6: H- -Arg-Arg-Hyp-Pro-Gly-Phe- Ser- -Tic-Pro-Arg- OH MS(FAB) :1244 (M+H) Example 7: H- -Arg- Arg-Hyp- Pro- Gly- Phe-Trp- -Tic- Phe-Arg- OH MS(FAB) :1393 (M+H) Example 8: H- -Arg-Arg-Hyp-Pro-Gly-Thia-Ser- (D)-Tic-Pro-Arg-OH 0 MS(FAB) :1250 (M+H) 00 90 Example 9: H- (D)-Arg-Arg-HYP-Pro-Gly-Thia- (D)-Asn- (D)-Tic-Thia-Arg-OH MS(FAB) :1333 (M+H) Example H- -Arg-Arg-Hyp-Pro-G1y-Thia-Opr- (D)-Tic-Thia-Arg-OH j t MS(FAB) :1301 (M+H) Example 11: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia- (D)-Gln- (D)-Tic-Thia-Arg-OH MS(FAB) :1347 (M+H) Example 12: H- -Arg-Arg-Hyp- Pro- Gly-Thia- Ser-Gly- -Tic-Pro-Arg-OH MS(FAB) :1307 (M+H) Example 13: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Phe-OH MS(FAB) 1241 (M+H) 25 Example 14: H- (D )-Arg- Arg-Hyp-Pro..Gly..mja-.Ser- -Tic-Pro-Phe-Arg
OH
MS(FAB) :1397 (M+H) Example H- -Arg-Arg-Hyp-Pro- Gly-Thia- Ser- B-Ala- -Tic-Pro-Arg- OH MS(FAB) :1321 (M+H) Example 16: H- (D)-Arg-Arg-Hyp-Pro- Gly-Thia- Gly- -Tic-Pro-Arg-OH MS(FAB) :1220 (M+H) Example 17: H- (D)-Arg-Arg-Aoc-Pro-Gly-Thia-Ser- (D)-Tic-Thia-Arg-OH MS(FAB) :1330 (M+H) Example 18: H- (D)-Arg-Arg-Pro-Aoc-Gly..Thia..Ser-.(D)-Tic-Thia-Arg-OH MS(FAB) :1330 (M+H) 0 Example 19: 0 0 H- -Arg- Arg- Hyp- Pro- Gly- Thia- Ser- -Tic-Aoc- Arg- OH MS(FAB) :1290 (M+H) Example H- (D)-Arg-Arg- Opr-Pro-Gly-Thia- Ser- (D)-Tic-Pro-Arg-OH 00:0 MS(FAB) :1236 (M+H) 00 Example 21: H- (D)-Arg-Arg-Pro-0pr-Gly-Thia-Ser- (D)-Tic-Pro-Arg-OH 0 MS(FAB) :1236 (M+H) Example 22: 00 H- -Arg- Arg- Hyp- Pro- Gly- Thia- Ser- -Tic- opr- Arg- OH MS(FAB) :1252 (M+H) Example 23: H- (D)-Arg- (D)-Ar;-HYP-Pro-GlyThia-Ser-(D) -Tic-Aoc-Arg-OH MS(FAB) 1290 (M+H) 26 Example 24: H- (D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser- (D)-Tic-Aoc-Arg-OH MS(FAB) 1290 (M+H) Examples 25 27:
OH
and H- -Arg-Arg-Pro-Hyp-Gly-Phe-Ser- -Tic-Phe-Arg(Mtr)
OH
and H- -Arg-Arg (Mtr) -Pro-Hyp-Gly-Phe-Ser- -Tic-Phe- Arg(Mtr)-OH are prepared analogously to Example 1, the splitting off of the side chain protective groups and the peptide from the resin by means of trifluoroacetic acid being limited to 30 minutes at room temperature. Under the conditions thus selected, only a negligible splitting off of the Mtr 6 protective group on the arginine takes place. The partially deblocked peptides are separated by chromatography on reverse phase material and purified.
46 9*25: H-(D)-Arg-Arg(Mtr)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe- Arg-OH MS(FAB): 1506 1 26: H- (D)-Arg-Arg(Mtr)-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Phe- 4 4 4Arg(Mtr)-OH L MS(FAB): 1718 (M+H) 27: H- (D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Phe-Arg(Mtr)-
OH
MS(FAB): 1506 (M+H) The peptides of Examples 28 31 below were prepared and purified analogously to Examples 25 -27.
Example 28: H-(D-r-rgMr-ypPo y-haSr(D)-Tic-Pro-Arg-OH MS(FAB) :1462 (M+H) i 27 Example 29: H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Arg(Mtr)-OH MS(FAB) 1462 (M+H) Example H-(D)-Arg-Arg(Mtr)-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Phe-OH MS(FAB) 1453 (M+H) Example 31: H-(D)-Arg-Arg(Mtr)-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH MS(FAB) 1502 (M+H) Example 32: H-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-NH-(CH 2 4
-NH
2 The peptide synthesis was carried out on 1 g of an aminomethyl resin which was modified with an attachment group of the type
C=C
o °Fmoc-NH-(CH 2 4 -NH-CO-O-CH2-C C-0-CH 2
-CO-
~c-c described in EP-A 264,802, using Fmoc-amino acid-OObt "j0 esters with an automatic peptide synthesizer (model 430A from Applied Biosystems) and synthesis programs which have themselves been modified. To this end, in each case 1 mmol of the appropriate amino acid derivative was weighed into the cartridges provided by the manufacturer, .15 and Fmoc-Arg(Mtr)-OH, Fmoc-Hyp-OH and Fmoc-(D)-Tic-OH were weighed into the cartridges together with 0.95 mmol 't of HOObt. The preactivation of these amino acids in situ was carried out directly in the cartridges by dissolving in 4 ml of DMF and adding 2 ml of a 0.55 M solution of -2 diisopropylcarbodiimide in DMF. The HOObt esters of the other amino acids were dissolved in 6 ml of NMP and then coupled to the resin previously deblocked using piperidine in DMF, like the amino acids preactivated in situ, the amino acids activated in situ being doubly coupled. After completion of synthesis, the peptide 4- S f, i -28aminobutylamide was split off from the resin with simultaneous removal of the side chain protective groups with trifluoroacetic acid which contained thioanisole and mcresol as cation entrainers. The residue obtained after stripping off the trifluoroacetic acid was repeatedly digested with ethyl acetate and centrifuged. The crude peptide which remained was chromatographed on OSephadex using 1N acetic acid. The fractions containing the pure peptide were combined and freeze-dried.
The compounds of Examples 33 35 were prepared analogously to Example 32: Example 33: -D-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-NH-(CH 2 4
-NH
2 Example 34: HOOC-(CH2)2-CO-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-NHd
(CH
2 4
-NH
2 'Aso Example 8844 S**a HOOC-(CH2)2-CO-(D)-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-NH-
(CH
2 4
-NH
2 The examples 36 to 161 were synthesized according to the method described under Example 1.
8844 Example 36: Arg-Arg-Hyp- Pro-Gly-Thia-Ser-Gly-(D)- Tic-Pro-Arg-OH MS(FAB) 1307 (M+H) Example 37: -Arg-Arg-Pro-Hyp-Gly-Thia-Ser-Gly-(D)-Tic-Pro-Arg- OH MS(FAB) 1307 (M+H) Example 38: H-(D-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(Dj-Tic-Pro-Phe-H MS(FAB) 1241 (M+H) i :1> -29- K Example 39: yp-rH- y-hiaSer-8-Ala- (D)-Tic-Aoc-Arg.OH MS(FAB) :1361 (M+H) Example H- Arg- Arg- Pro-Hyp- Gly- Thjia- Ser- A- Ala- -Tic-Aoc-Arg- 01- MS(FAB) :1361 (M+H) Example 41: H- -Arg-Arg-Hyp-Pro-Gly-Thia- Ser- (D)-Tic-Pro-Phe-Arg- OH MS(FAB) :1397 (M+H) Example 42: Hi-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser- (D)-Tic-Pro-Phe-Arg-OH MS(FAB) :1397 (M+H) Example 43: H- -r-AgPr-Gpc ly-ThaGY(D) -Tic-Aoc-Arg-OH o MS(FAB) :1260 (M+H) Example 44: H- Arg- Arg- Hyp- Pro- Gly-Thia-Gly (D)-Tic-Aoc-Arg-OH MS(FAB) :1260 (M+H) Example H- -Arg- (D)-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg
OH
MS(FAB) :1290 (M+H) Example 46: H- -Arg- -Arg-Pro-Hyp-GlyThia-Ser-(D) -Tic-Aoc-Arg-
OH
?4S(FAB) :1290 (N+H) Example 47: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser- (D)-Tic-Tic-Arg-OH MS(FAB) :1312 (M+H) Example 48: -Arg- Arg- Pro-Hyp- Gly-Thia- Ser- -Tic-Tic-Arg- OH ?4S(FAB) 1312 (M+H) Example 49: H- (D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser- (D)-Tic-Aoc-Arg-OH MS(FAB) :1274 (M+H) Example H- (D)-ArgArgHypProGlyThia-(D)-Tic-Aoc-Arg-OH MS(FAB) :1203 (M+H) Example 51: Hi-(D- -AgHpPr-l-AcS -Tic-Aoc-Arg-CoH MS(FAB) :1274 (M+H) Example 52: H- (D-r-r-Y-r-l-haAAa (D)-Tic-Aoc-Arg-OH MS(FAB) :1274 (M+H) Example 53: H- (D)-Arg-Arg-Pro-Hyp-Gly-Thia-A-Ala- -Tic-Aoc-Arg-OH o ?'S(FAB) :1274 (M+H) Example 54: H- -Arg- Arg-Hyp- Pro- Gly- Asp- Ser- -Tic- Aoc-Arg- OH MS(FAB) :1252 (M+H) 0 to Example MS(FAB) :1252 (M+H) too Example 56: H- -Arg- Arg- Hyp- Pro- Gly- Trp- Ser- -Tic- Aoc-Arg- OH MS(FAB) :1323,7 (M+H) Example 57: H- -Tyr-Arg-Pro-Hyp-Gly- Thia- Ser- -Tic-Aoc-Arg- OH MS(FAB) :1297,7 (M+H) 10 Example 58: H- -Arg-Arg-Pro-Hyp-Gly-Thia-Ser- -Tic- -Oic-Arg-OH MS(FAB) :1304,6 (M+H) Example H- -Ar MS (FAB) Example 64 H- -Arg- MS (FAB) Example 6 H- -Arc MS (FAB) Example 6 31 g-Ar-Pr-HypGlyThiaSer(D) -Tic-Oic-Arg-OH :1304,6 (M+H) Arg-Pro-Pro-Gly-Tmia-.Ser- -Tic-Oic-Arg-OH 1289 (M+H) 1: ;-Lys- Pro-Hyp- Gly-Thia-Ser-.(D) -Tic-Aoc-Arg- OH :1262 (M+H) 2: H- (D)..Arg..Lys..pro.Hyp..Gly..mia-Ser.(D)-.Tic..Oic..Arg..OH MS(FAB) :1276 (M+H) Example 63: ft t f-f ~f I f f I
II
f f f i I t I If I S I SI 1 6 I II fIll I I II I H- -Arg-Lys-pro-Pro-Gly.Thia..Ser-.(D) -Tic-Oic-Arg-OH ?4S(FAB) :1260 (M+H) Example 64: H- -Arg-Arg- Pro-Hyp- Gly-Phe- Ser- (D)..Tic..Oic..Arg..OH MS(FAB) 1298 (M+H) Example H- (D)-.Arg.Arg.Hyp.Pro-Gly-Phe- Ser- -Tic-Oic-Arg- OH MS(FAB) :1298 (M+H) Example 66: H- (D).Arg-Arg-Pro-Pro-Gly-Phe-Ser- (D)-Tic-Oic-Arg-OH MS(FAB) :1282 (M+H) Example 67: H- (D)-Arg-Arg(NO 2 )-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Aoc-Arg-0H MS(FAB) :1329,7 (M+H) Example 68: H- (D)-Arg-Arg(NO, 2 )-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Oic-Arg-OH MS(FAB): 1343 (M+H)
'I
A
-32 Exampl'e 69: H- (D)-Arg-Arg(NO 2 )-Pro-Pro-Gly-Phe-Ser- (D)-Tic-Oic-Arg-OH MS(FAB) :1327 (M+H) Example H- (D)-Arg-Arg(N0 2 )-Pro-Pro-Gly-Thi4-Ser- (D)-Tic-Oic-Arg-OH MS(FAB) :1333 (M+H) Example 71: H- (D)-Arg-Arg(N0 2 )-Pro-Hyp-Gly-Thia-Ser- (D)-Tic-Oic-Arg-OH MS(FAB) :1349 (M+H) Example 72: H-Ar; (Tos )-Pro-Hyp- Gly-Thia- Ser-D-Tic- Oic-Arg- OH MS(FAB) 1302 (M+H) Example 73: H- Arg-Pro- Hyp- Gly- Phe- Ser-D- Tic- Oic- Ar;-OH MS(FAB) :1142 (M+H) Example 74: H- Lys CO- NH- C 6
H
5 -Pro- Hyp- Gly- Phe- Ser-D- Tic- Oic- Ar;-OH MS(FAB) :1233 (M+H) tt Example H-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH MS(FAB) :1296 (M+H) Example 76: H- Lys (Nicotinoyl Pro- Hyp- Gly- Phe- Ser-D- Tic- Oic- Ar;- OH MS(FAB) :1219 (M+H) Example 77: H-Ar; (Tos Pro- Hyp- Gly- Phe- Ser- D- Tic- Aoc- Ar;- OH MS(FAB) 1282 (M+H) -33- Example 78: Ac-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH MS(FAB) :1324 (M+H) Example 79: H- D-Arg- Arg (Tos) -Pro-Hyp- Gly- Phe- Ser- D-Tic-Aoc- Arg- OH MS(FAB) :1438 (M+H) Example H- Arg (Tos Hyp- Pro- Gly- Thia- Ser- D- Tic- Oic- Arg- OH MS(FAB) :1302 (M+H) Example 81: H- Arg- Hyp- Pro- Gly- Phe- Ser-D- Tic- Oic-Arg- OH too 0. MS(FAB) 12 (M+H) 5 Example 82: H-Lys os)-H)-Hyp-Pro- Gly-Phe- Ser-D-Tic-Oic-Arg-OH 0 MS(FAB) :19 MH 00 Example 83: H- Arg (Tio y) Hyp Pro- Gly- Phe- Ser-D- Tic- Oic-Arg- OH 0 MS(FAB) :1286 (M+H) MSFB 1340MH 0 Example 84: H- Arg (Tos Hyp- Pro- Gly- Phe- Ser- D- Tic-Aoc- Arg- OH MS(FAB) :1238 (M+H) Example 88: 34 444444 4 4 4. 4, 4 4
S
4,4, o 4 4* 4 4* *0 H-Ar; (Tos -Pro- Pro- Gly- Thia- Ser-D- Tic- Qic- Arg- OH MS(FAB) :1286 (M+H) Example 89: H-Arg- Pro-Pro- GI.y- Phe- Ser- D- Tic- Qic- Arg- OH MS(FAB) :1126 (M+H) Example H- Lys Ca-NH- C 6 H Pro- Pro- Gly- Phe- Ser-D- Tic- Oic- Ar;-OH MS(FAB) :1217 (M+H) -Example 91: H- Arg (Tos -Pro- Pro- Gly- Phe- Ser-D- Tjc- Dic- Ar;-OH MS(FAB) :1280 (M+H) Example 92: H-Lys(Nicotinoyl)-Prc-Pro-Gly-Phe-Ser-D-Tic-Oic-Ar-OH MS(FAB) :1203 (M+H) Example 93: H-Ar; (Tos Pro- Pro- Gly- Phe- Ser- D- Tic- Aoc- Ar;-OH MS(FAB) :1266 (M+H) Example 94: Ac-Ar; (Tos) -Pro-Pro- Gly-Phe- Ser-D- Tic-Aoc-Arg- OH MS(FAB) :1308 (M+H) Example H-D-Arg-Arg (Tos) -Pro- Pro- Gly- Phe- Ser-D-Tic-Aoc-Arg- OH MS(FAB) :1422 (M+H) 4 440 4 4 14 4 I 44 4 4 4 44 4 44 11-4 4 4 Example 96: H- Ar;-Pro- Hyp- Gly- Thia- Ser- D- Tic- Oic- Ar;- OH MS(FAB) :1148 (M+H) Example 97: H- Lys CO- NH- C 6
H
5 -Pro- Hyp- Gly- Thia- Ser-D- Tic- Oic-Ar;- OH MS(FAB) :1239 (M+H)
A
Example 98: H-Lys(Nicot:
MS(FAB):I
Example 99: 35 inoyl)-ProHypGly.Th±-SerDTicOicArg-OH ?25 (M+H) H- Arg (Tos -Pro- Hyp- Gly- Thia- Ser- D- Tic- Aoc- Arg- OH MS(FAB) :1288 (M+H) Example 100: Ac- Arg (Tos Pro- Hyp- Gly- Thia- Ser- D- Tic- Aoc- Arg- OH MS(FAB) :1330 (M+H) Example 101: H-D-Arg-Arg (Tos) -Pro-Hyp- Gly-Thia- Ser-D-Tic-Aoc-Arg- OH MS(FAB) :1444 (M+H) Example 102: H- Arg- Hyp- Pro- Gly- Thi a- Ser-D- Tic- Oic- Arg- OH MS(FAB) :1148 (M+H) t 4 44 4 4 4 4444 44 4 5 I t4*I 4 4 4 44 4 44 II I 4 1 I 4 Example 103: 4444 I I 4 41 1 4 44 I I 4 4 44 4 1* 14 4 Ce., 4 4 4 4* 4 H- Lys CO- NH- C 6
H
5 -Hyp- Pro- Gly- Thi a- Ser- D- Tic- Oic- Arg- OH MS(FAB) :1239 (M+H) Example 104: H- Lys (Nicotinoyl )-Hyp- Pro- Gly-Thia- Ser-D- Tic- Oic-Arg- OH MS(FAB) :1225 (M+H) Example 105: H-Arg(Tos)-H-p-Pro-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH MS(FAB) :1288 (M+H) Example 106: Ac-Arg(Tos)-Hyp-Pro-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH MS(FAB) :1330 (M+H) Example 107: H- D-Arg- Arg (Tos -Hyp- Pro- Gly-Thia- Ser-D-Tic-Aoc-Arg- OH MS(FAB) :1440 (M+H)
I
-36- Example 108: H-Lys (-CO-NH- C 6
H.
5 -Pro-Fro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH M'S(FAB) :1225 (M+H) Example 109: H- Lys (Nicotinoyl -Pro- Pro- Gly- Thia- Ser- D- Tic- Oic- Arg- OH M~S(FAB) :1209 (M+H) Example 110: H-Arg(Tos) -Pro-Pro-Gly- Thia- Ser-D- Tic-Aoc-Arg-OH MS(FAB): 1272 (M+H) Example 111: Ac-Arg(Tos)- Pro-Pro-Gly- Thia- Ser-D-Tic-Aoc-Arg-OH MS(FAB) :1314 (M+H) Example 112: H -D-Arg-Arg(Tos )-Pro-Pro- Gly-Thia- Ser-D-Tic-Aoc-Arg-OH M'S(FAB) :1428 (M+H) Example 113: H-D-Arg-Lys(Nicotinoyl)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic- Arg-OH MS(FAB) 1365 (M+H) Example 114: H- D- Arg- Lys CO-NH-C CH 5 Pro- Pro- Gly- Thia- Ser- D- Tic- Qic- Arg-O M]S(FAB) 1379 (M+H) 4 Example 115: H- D-Arg- Arg (Tos Pro- Pro- Gly- Thia- Ser-D- Tic- Oic- Arg- OH VMS(FAB) :1442 (M+H) Example 116: H-Lys-Lys- (Nicotinoyl )-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-
OH
MS(FAB) 1337 (M+H) -37- Example 117: H- Lys- Lys (-CO-NH- C 6
H.
5 -Pro-Pro- Gly- Thia- Ser-D- Tic- Qic- Arg-
OH
MS(FAB) :1351 (M+H) Example 118: H-Lys-Arg(Tos)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS(FAB) :1414 (M+H) I. Example 119: H-D--Arg- Lys (Nicotinoyl -Pro-Hyp- Gly- Thia- Ser-D- Tic- Oic-Arg-
OH
MS(FAB) :1381 (M+H) *#tot: 0 O Example 120: eve: H-D-Arg-Lys- (CO-NH-C H 5 -Pro-Hyp-Gly-Thia-Ser-D-Tic-Oico a a Arg-OH 00 0 00 .0 MS(FAB) 1395 (M+H) Example 121: H-D-Arg-Arg(Tos) -Pro-Hyp-Gly-Thia-Ser-D-Tic- Oic-Arg- OH MS(FAB) :1458 (M+H) Example 122: 0 H-Lys-Lys (-CO-NH-C 6
H,
5 -Pro-Hyp-Gly-Thia-Ser-D-Tic- Oic- Arg-OH MS(FAB) 1367 (M+H) t Example 123: H-Lys-Lys (Nicotinoyl )-Pro-Hyp- Gly-Thia- Ser-D-Tic-Oic-Arg-
OH
MS(FAB) :1353 (M+H) Example 124; H-Lys-Arg(Tos) -Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MOS(FAB) 1430 (M+H) 38-- Example 125: H- D-Arg- Lys (Nicotinoyl) -ProProGy- Phe-SerD Tic- Oc- Arg-
OH
MS(FAB) 1359 (M+H) Example 126: H- D-Arg- Lys NH- C 6 H -Pro- Pro- Gly- Phe- Ser-D- Tic- Qic- Arg-
OH
MS(FAB) :1373 (M+H) Example 127: H-D-Arg-Arg(Tos)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH MS(FAB) :1436 (M+H) Example 128: H-Lys-Lys (Nicotinoyl )-Pro-Pro-Gly-Phe- Ser-D-Tic-Oic-Arg- OH MS(FAB) 1331 (M+H) 9 Example 129: H- Lys- Lys CO- NH- C 6 H Pro- Pro- Gly- Phe- Ser- D- Tic- Oic- Arg- OH MS(FAB) :1345 (M+H) Example 130: 4 4 MS(FAB) 1408 (M+H) Example 131: H- D-Arg- Lys (Nicot inoyl) -Pro- Hyp- Gly- Phe-S er- D- Tic- Oic- Arg-
OH
?4S(FAB) :1375 (M+H) Example 132: H- D-Arg- Lys CO- NH- C 6
H
5 -Pro- Hyp- Gly- Phe- Ser-D- Tic- Oic- Arg-
OH
MS(FAB) :1389 (M+H) Example 133: H- D-Arg- Arg (Tos -Pro-Hyp- Gly- Phe- Ser-D- Tic- Oic-Arg- OH MS(FAB) 1452 (M+H) -39j Example 134: H- Lys- Lys (Nicot inoy) -Pro- Hyp- Gy-Phe- Ser D-Tic-..Oic-Arg-OH :1347 (M+H) Example 135: H-Lys-Lys (-CO-Nli-C H 5 -Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-
OH
MS(FAB) :1361 (M+H) Example 136: H- Lys-Arg (Tos) -Pro- Hyp- Gly- Phe- Ser-D- Tic- Oic-Arg- OH MS(FAB) :1424 (M+H) Example 137: *H-D-Arg- Orn (Nicotinoyl) -Pro- Pro- Gly- Thia- Ser-D-Tic- Oic- Arg-
OH
P MS(FAB) :1351 (M+H) Example 138: H- D-Arg- Orn CO- NH- C 6
H
5 )-Pro- Pro- Gly- Thia- Ser-D- Tic- Oic- Arg-OH 0 0~4 0 00 00 0 0 00 P 0 0 0 00 0 04 04 0 4 00 0040 0 00 00 0 MS(FAB) :1428 (M+H) Example 139: H- Lys- Orn (Nicotinoyl) -Pro- Pro- Gly-Thia- Ser- D-Tic- Oic-Arg-
OH
MS(FAB) :1323 (M+H) Example 140: H- Lys- Cm CO-NH- C 6
H
5 -Pro- Pro- Gly-Thia- Ser-D-Tic- Oic-Arg- OH ?4S(FAB) :1337 (M+H) Example 141: H- D-Arg- Orn (Nicotinoyl) -Pro- Hyp- Cly-Thia- Ser- D-Tic- Oic-Arg-
OH
MS(FAB) :1367 (M+H) Example 142: H- D-Arg- Orn CO- NH- C 6
H
5 )-Pro-Hyp- Gly-Thia- Ser-D-Tic- Qic- Arg-OH MS(FAB) :1381 (M+H) Example 143: H-Lys-Orn(Nicotinoyl)-Pro-Hyp-Gly-Thia-Ser-D-Tic.Oic-Arg.OH MS(FAB) 1339 (M+H) Example 144: H- Lys- Orn -CO-NH- C 6
H
5 -Pro- Hyp- Gly- Thia- Ser- D- Tic- Qic- Arg-
OH
MS(FAB) :1353 (M+H) Example 145: H- D-Arg- Orn (Nicotinoyl )-Pro- Pro- Gly- Phe- Ser- D- Tic- Oic- Arg-
OH
MS(FAB) 1345 (M+H) Example 146: H- D- Arg- Orn CO- NH- C 6
H
5 -PoPoAl-Pe er -Tc i-A
OH
MS(FAB) :1359 (M+H) 4 4 Example 147: H-Lys-Orn(Nicotinoyl)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH MS(FAB) :1317 (M+H) Example 148: H-Lys-Din CO-NH- C 6
H
5 -Pro-Pro- Gly- Phe- Ser-D-Tic- Dic-Aing-
OH
MS(FAB) :1331 (M+H) Example 149: H- D-Arg- Orn (Nicotinoyl -Pro-Hyp- Gly- Phe- Ser- D- Tic- Dic- Arg-
OH
MS(FAB) 1361 (M+H) 41 Example 150: H- D-Arg- in (CD- NH- C 6
H
5 -Pro- Hyp- Gly- Phe- Ser- D- Tic- Qic- Arg-
OH
MS(FAB) :1375 (M+H) Example 151: H- Lys-Din (Nicotinoyl -Pro- Hyp- Gly- Phe- Ser- D-Tic- Oic- Aig- OH MS(FAB) :1333 (M+H) Example 152: H- Lys-Din CD-NH-C 6
H,
5 -Pro-Hyp- Gly-Phe- Ser- D-Tic- Dic- Aig-
OH
MS(FAB) :1347 (M+H) Example 153: H-Lys-Lys-Pro-Pro-Gly-Thia- Ser- -Tic-Aoc-Arg-OH #fit MS(FAB) :1218 (M+H) Example 154: H- Lys-Lys-Pro-Hyp- Gly-Thia-Ser- -Tic-Aoc-Arg- OH MS(FAB) :1234 (M+H) Example 155: H-Lys-Lys-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH t It MS(FAB) :1234 (M+H) rt t Example 156: IA.H-Lys-Lys-Pro-Pro-Gly-Phe- Ser- -T.:.c-Aoc-Arg- OH tt t S(FAB) :1212 (M+H) Example 157: H- Lys-Lys- Pro-Hyp-Gly-Phe- Ser- -Tic-Aoc-Arg-DH MS(FAB) :1228 (M+H) Example 158: H-Lys-Lys-Pro-Pro-Gly-Thi.a- Ser- -Tic-Oic-Arg-OH MS(FAB) 1232 (M+H) 42 A Example 159: H-Lys-Lys-Pro-Hyp-Gly-Thia-Ser- (D)-Tic-Oic-Arg-OH MS(FAB) :1248 (M+H) Example 160: H-Lys-Lys--Hyp-Pro-Cly-Thia- Ser- -Tic- Oic-Arg-OH MS(FAB) :1226 (M+H) Example 161: H-Lys-Lys- Pro-Hyp- Gly-Phe- Ser- (D )-Tic-Oic-Arg- OH MS(FAB) :1242 (M+H) The Examples 162-164 were prepared analogously to Example 32 using the resin having the structure Fmoc-NH OCH: 3
OCH
3
CH
2
OH
CH
2 4,46 NH tC" 2 (polystyrene) 4 described in EP-A 322,348.
Example 162: 1?H- D- Arg- Arg- Pro- Hyp- Gly- Phe- Ser- D- Tic- Aoc- Arg- NH 2 .MS(FAB) :1283 (M+H) Example 163: H- D- Arg- ARg- Hyp- Pro- Gly- Phe- Ser- D- Tic- Aoc- Arg- NH 2 MS(FAB): 1283 (M+H) Examp
H-D-A
MS (FA 43 le 164: rg- Arg- Pro- Pro- GJly- Phe- Ser- D- Tic- Aoc-Arg- NH 2 1267 (M+H) ~ftt ~z't a ill 2 t 2 at 21 ft a a t a ''at a a at a a ft a f a I aa at:a a~j
Claims (5)
1. A peptide of the formula I A-B-C-E-F-K- (D)-Tic-G-M-F'-I I 0000 rI 0 0 00 00 o o 0 0000 0000 0000 0 0 00 0 00 00 0 0 0 o 0 A 0000 00 0 0 00 00 1 0 00 00 0 0001 0 0 0 00 I in which A denotes hydrogen, (C 1 -alkyl, -alkanoyl, (Cl-Cs)-alkoxycarbonyl or (Cl-C 8 -alkylsulf onyl, in which in each case 1, 2 or 3 hydrogen atoms are optionally replaced by 1, 2 or 3 identical or different radicals from the series comprising carboxyl, amino, (Cl-CA) -alkyl amino, hydroxyl, (Cl-CO)-alkoxy, halogen, di- (Cl-CA) -alkylamino, carbamoyl, sulfamoyl, (Cl-CA) -alkoxycarbonyl, (C6-C 1 2 -aryl and (C,-C 12 )-aryl-(Cj-C 5 )-alkyl, or in which in each case 1 hydrogen atom is optionally replaced by a radical from the series comprising (C 3 -cycloalkyl, (Cl-C 4 -alkylsulfonyl, (Cl-CA) -alkylsulfinyl, (C.-C 1 2 -aryl- (C 1 -C 4 -alkylsulf onyl, (C 6 -aryl- Cl-C 4 -alkylsulf inyl, (Cr.-C 1 2 -aryloxy, (C 3 -heteroaryl and (C 3 -Cg) -heteroaryloxy and 1 or 2 hydrogen atoms are replaced by 1 or 2 identical or different radicals from the series comprising ca~rboxyl, amino, (C,-C 4 -alkylamnino, hydroxyl, -alkoxy, halogen, di- (Cl-C 4 -alkyl amino, carbamoyl, sulfamoyl, -alkoxycarbonyl, (C 6 -C 12 )-aryl and C 6 -C 12 -aryl- (C 1 -C. 5 -alkyl, a 2 denotes (C 3 -C)-cycloalkyl, carbainoyl, which may be optionally substituted on the nitrogen by (C-C)-alkyl or (Cr,-C 1 2 )-aryl, (C 6 -C 12 -aryl 0 (C, 6 -arylsulfonyl or 0 (C 3 -heteroaryl or (C 3 -heteroaryloyl, where in the radicals def ined under and a 2 in each case heteroaryl, aryloyrl, arylsulfonyl and heteroaryloyl is optionally substituted by* 1, 3 or 4 identical or *0:0 different radicals from the series comprising carboxyl, amino, nitro, -alkyl amino, hydroxyl, (Cl-CA) -alkyl, -alkoxy, halogen, cyano, di- (C,-C 4 -alkylainino, carbamoyl, sulfamoyl and (Cl-CA) -alkoxycarbonyl, or -46 a 3 denotes a radical of the formula II R N CH- C R2 13 (II) Ri is defined as A under or a 2 R 2 denotes hydrogen or methyl, R 3 denotes hydrogen or (Cl-C,)-alkyl, preferably (Cl-C)-alkyl, which is optionally monosubstituted by amino, substituted amino, hydroxyl, carboxyl, carbamoyl, guanidino, substituted guanidino, ureido, mercapto, methylmercapto, 0: phenyl, p 4-chlorophenyl,
4-fluorophenyl, 4-nitrophenyl, 4-methoxyphenyl, 4-hydroxyphenyl, ::-phthalimido, 4-imidazolyl, 3-indolyl, 2-thienyl, 3-thienyl, J 2-pyridyl, 3-pyridyl or cyclohexyl, where substituted amino stands for a compound -NH-A- and substituted guanidino stands for a compound -NH-C(NH)-NH-A, in which A is defined as under or a 2 B stands for a basic amino acid in the L- or D-con- figuration, which may be substituted in the side chain; La 47 C stands for a compound of the formula liIa or IIIb G'-G'-Gly G'-NH-(CH 2 )n-CO (IIIa) (IIIb) in which G' independently of one another denotes a radical of the formula IV R 4 R 5 0 I 1 II N CH C (IV) in which R 4 and R 5 together with the atoms carrying them fcrm a heterocyclic mono-, bi- or tricyclic ring system having o 2 to 15 carbon atoms, and n is 2 to 8; o oE stands for the radical of an aromatic amino acid; Bo 0 F independently of one another denotes the radical of a neutral, acidic or basic, aliphatic or aromatic amino acid which may be substituted in the side chain, or stands for a direct bond; (D)-Tic denotes the radical of the formula V SH O I r (v) G is as defined above for G' or denotes a direct bond; F' is as defined for F, denotes a radical -NH-(CH 2 1 i*,\with n 2 to 8, or, if G does not denote a direct bond, carn stand for a direct bond, and I is -OH, -NH 2 or -NHC 2 H, K denotes the radical -NH-(CH 2 with x 1-4 or stands for a direct bond, and M is as defined for F, and their physiologically tolerable salts. 2. A peptide of the formula I as claimed in claim 1, in which B denotes Arg, Lys, Orn, 2,4-diaminobutyroyl or an L- homoarginine radical, where in each case the amino or guanidino group of the side chain may be sub- 48 stituted by A as 'scribed under or a 2 in claim E stands for the radical of an aromatic amino acid in the L- or D-configuration, which contains 6 to 14 carbon atoms in the aryl moiety as ring members, such as phenylalanine which is optionally substi- tuted by halogen in the 3- or 4-position, tyrosine, O-methyltyrosine, 2-thienylalanine, 2- pyridylalanine or naphthylalanine; denotes the radical of a basic amino acid in the L- 0 e. or D-ccnfiguration, such as Arg or Lys, where the guanidino group or amino group of the side chain may o be replaced by A as described under or a 2 in claim 1, or denotes a radical -NH-(CH 2 with n 2 to 8 and K stands for the radical -NH-(CH 2 )z-CO- with x 2-4 00*4 or denotes a direct bond. o 00 3. A peptide of the formula I as claimed in claim 1 and/or 0 0 2 in which B denotes Arg, Orn or Lys, where the guanidino group c 0or the amino group of the side chain is unsubsti- tuted or may be substituted by (Cl-C,)-alkanoyl, (C 7 C 13 )-aryloyl, (C 3 -C,)-heteroaryloyl, (Cl-C,)-alkylsul- fonyl or (C,-C 12 )-arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted, as described under a 2 with 1, 2, 3 or 4 identical or different radicals. E denotes phenylalanine, 2-chlorophenylalanine, 3-chlorophenylalanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, tyrosine, 0-methyltyrosine or f-(2-thienyl)alanine; 49 K stands for a direct bond and M stands for a direct bond. 4. A peptide of the formula I as claimed in one or more of claims 1 to 3 in which A denotes hydrogen, or (L)-H-Arg, or Lys or or (L)-H-Orn; B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain may be sub- stituted by hydrogen, (C1-C 8 )-alkanoyl, (C,-C 13 aryloyl, (C 3 -C,)-heteroaryloyl,(C 1 -C 8 )-alkylsulfonyl or (C,-C 2 )-arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted with 1, 2, 3 or 4 identi- cal or different radicals from the series comprising methyl, methoxy and halogen. 0 19 C denotes Pro-Pro-Gly, Hyp-Pro-Gly or Pro-Hyp-Gly E denotes Phe or Thia F denotes Ser, Hser, Lys, Leu, Val, Nle, Ile or Thr K stands for a direct bond M stands for a direct bond G stands for the radical of a heterocyclic ring system of the formula IV, where the radicals of the hetero- cycles pyrrolidine piperidine tetrahydro- isoquinoline cis- and trans-decahydroisoquino- line cis-endo-octahydroindole cis-exo- octahydroindole trans-octahydroindole cis- endo-, cis-exo-, trans-octahydrocyclopentano(b]pyr- role, or hydroxyproline are preferred. F denote Arg and I stands for OH. The preparation of a peptide of the formula I as claimed in one or more of claims 1 to 4, which comprises a) reacting a fragment having a C-terminal free car- boxyl group or its activated derivative with an appropriate fragment having an N-terminal free amino group or b) synthesizing the peptide stepwise, optionally splitting off one or more protective groups temp- orarily introduced for the protection of other functions in the compound obtained according to (a) or and optionally converting the compounds of the formula I thus obtained into their physiologically tolerable salt.
6. Use of a peptide of the formula I as claimed in one or more of claims 1 to 4 as a medicament.
7. Use of a peptide of the formula I as claimed in one or So'9t more of claims 1 to 4 for the treatment of pathological states which are mediated, caused or supported by brady- kinin and bradykinin-related peptides. oao o i;
8. A pharmaceutical agent containing a peptide of the formula I as claimed in one or more of claims 1 to 4. DATED this 8th day of August 1989. HOECHST AKTIENGESELLSCHAFT WATERMARK PATENT TRADEMARK ATTORNEYS QUEEN STREET MELBOURNE. VIC. 3000.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3839581 | 1988-11-24 | ||
| DE3839581 | 1988-11-24 | ||
| DE3916291 | 1989-05-19 | ||
| DE3916291 | 1989-05-19 | ||
| DE3918225 | 1989-06-03 | ||
| DE3918225 | 1989-06-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3943189A AU3943189A (en) | 1990-05-31 |
| AU612054B2 true AU612054B2 (en) | 1991-06-27 |
Family
ID=27198531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU39431/89A Expired AU612054B2 (en) | 1988-11-24 | 1989-08-09 | Peptides having bradykinin antagonist action |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0370453B1 (en) |
| JP (1) | JPH07121956B2 (en) |
| KR (1) | KR0139632B1 (en) |
| CN (1) | CN1035006C (en) |
| AT (1) | ATE107318T1 (en) |
| AU (1) | AU612054B2 (en) |
| CA (1) | CA1340667C (en) |
| CY (2) | CY2028A (en) |
| CZ (1) | CZ282384B6 (en) |
| DE (3) | DE122008000066I2 (en) |
| DK (1) | DK175344B1 (en) |
| ES (1) | ES2057071T3 (en) |
| FI (1) | FI94353C (en) |
| HK (1) | HK1006716A1 (en) |
| HU (2) | HU210566B (en) |
| IE (1) | IE63490B1 (en) |
| IL (1) | IL91298A (en) |
| LU (1) | LU91499I2 (en) |
| LV (1) | LV10720B (en) |
| MX (1) | MX9203277A (en) |
| NL (1) | NL300359I2 (en) |
| NO (2) | NO177597C (en) |
| NZ (1) | NZ230244A (en) |
| PH (1) | PH31009A (en) |
| PT (1) | PT91692B (en) |
| SK (1) | SK279315B6 (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648333A (en) * | 1988-11-24 | 1997-07-15 | Hoechst Aktiengesellschaft | Peptides having bradykinin antagonist action |
| DE4013270A1 (en) * | 1990-04-26 | 1991-10-31 | Hoechst Ag | PEPTIDES WITH BRADYKININ ANTAGONISTIC EFFECT |
| WO1991009055A1 (en) * | 1989-12-08 | 1991-06-27 | Boston University | Acylated bradykinin antagonists and uses therefor |
| MX9100717A (en) * | 1990-08-24 | 1992-04-01 | Syntex Inc | BRADIQUININE ANTAGONISTS |
| US5843900A (en) * | 1991-04-01 | 1998-12-01 | Cortech, Inc. | Bradykinin antagonists |
| US5416191A (en) * | 1991-04-01 | 1995-05-16 | Cortech, Inc. | Bradykinin antagonists |
| US6770741B1 (en) | 1991-04-19 | 2004-08-03 | Scios Inc. | Bradykinin antagonist peptides |
| DE69231918D1 (en) * | 1991-04-19 | 2001-08-09 | Scios Nova Inc | PEPTIDANTAGONISTS OF BRADYKININ |
| DE69226708T2 (en) | 1991-04-19 | 1999-04-15 | Scios Nova Inc., Mountain View, Calif. | BRADYKININ TYPICAL PEPTIDES |
| HUT63060A (en) * | 1991-08-22 | 1993-07-28 | Hoechst Ag | Process for producing pharmaceutical compositions locally applicable on nose and eye, comprising bradykinin antagonists |
| US6117974A (en) * | 1991-10-02 | 2000-09-12 | Peptor Limited | Libraries of backbone-cyclized peptidomimetics |
| WO1993011789A1 (en) | 1991-12-12 | 1993-06-24 | Scios Nova Inc. | Modified position (7) bradykinin antagonist peptides |
| TW199863B (en) * | 1991-12-21 | 1993-02-11 | Hoechst Ag | |
| WO1993017701A1 (en) * | 1992-03-12 | 1993-09-16 | The Administrators Of The Tulane Educational Fund | Endothelin receptor-binding peptides |
| TW258739B (en) * | 1992-04-04 | 1995-10-01 | Hoechst Ag | |
| FR2692581B1 (en) * | 1992-06-18 | 1994-08-19 | Adir | New peptide derivatives with bradykinin antagonist activity, their preparation process and the pharmaceutical compositions containing them. |
| US5610142A (en) * | 1992-10-08 | 1997-03-11 | Scios Inc. | Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids |
| US5541286A (en) * | 1992-10-08 | 1996-07-30 | Scios Nova Inc. | Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids |
| US5686565A (en) * | 1992-10-08 | 1997-11-11 | Scios Inc. | Bradykinin antagonist pseudopeptide derivatives of aminoalkanoic acids and related olefins |
| US5521158A (en) * | 1992-10-08 | 1996-05-28 | Scios Nova Inc. | Pseudopeptide bradykinin receptor antagonists |
| IL107400A0 (en) * | 1992-11-10 | 1994-01-25 | Cortech Inc | Bradykinin antagonists |
| WO1994019372A1 (en) * | 1993-02-17 | 1994-09-01 | Scios Nova Inc. | Cyclic bradykinin antagonist peptides |
| US5817756A (en) * | 1993-09-09 | 1998-10-06 | Scios Inc. | Pseudo- and non-peptide bradykinin receptor antagonists |
| DE4345062A1 (en) * | 1993-12-31 | 1995-07-13 | Hoechst Ag | Use of bradykinin antagonists for the manufacture of medicaments for the treatment of viral diseases |
| CA2184824A1 (en) * | 1994-03-09 | 1995-09-14 | Val S. Goodfellow | Bradykinin antagonist peptides incorporating n-substituted glycines |
| US6407059B1 (en) | 1994-06-08 | 2002-06-18 | Peptor Limited | Conformationally constrained backbone cyclized peptide analogs |
| IL109943A (en) * | 1994-06-08 | 2006-08-01 | Develogen Israel Ltd | Conformationally constrained backbone cyclized peptide analogs |
| EP0832106A2 (en) * | 1995-06-05 | 1998-04-01 | Cortech, Inc. | Compounds having bradykinin antagonistic activity and mu-opioid agonistic activity |
| US5770687A (en) * | 1995-06-07 | 1998-06-23 | Peptor Limited | Comformationally constrained backbone cyclized somatostatin analogs |
| US6051554A (en) * | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| FR2737408B1 (en) * | 1995-07-31 | 1997-09-05 | Oreal | USE OF A BRADYKININE ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED |
| US5834431A (en) * | 1995-09-08 | 1998-11-10 | Cortech, Inc. | Des-Arg9 -BK antagonists |
| US5849863A (en) * | 1995-09-08 | 1998-12-15 | University Of Colorado | Cytolytic bradykinin antagonists |
| FR2739553B1 (en) | 1995-10-06 | 1998-01-02 | Oreal | USE OF BRADYKININE ANTAGONISTS TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP THE HAIR LOSS |
| US6841533B1 (en) | 1995-12-07 | 2005-01-11 | Peptor Limited | Conformationally constrained backbone cyclized interleukin-6 antagonists |
| DE19612067A1 (en) * | 1996-03-27 | 1997-10-02 | Hoechst Ag | Use of bradykinin antagonists for the manufacture of medicaments for the treatment of chronic fibrogenetic liver diseases and acute liver diseases |
| US6355613B1 (en) | 1996-07-31 | 2002-03-12 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| DE19642289A1 (en) | 1996-10-14 | 1998-04-16 | Hoechst Ag | Use of bradykinin antagonists for the manufacture of medicaments for the treatment and prevention of Alzheimer's disease |
| DE10304994A1 (en) * | 2003-02-07 | 2004-09-02 | Aventis Pharma Deutschland Gmbh | The use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis |
| CN102532267B (en) * | 2012-02-09 | 2014-06-18 | 深圳翰宇药业股份有限公司 | Method for preparing icatibant |
| CN104043101B (en) * | 2014-05-23 | 2016-04-20 | 杭州阿德莱诺泰制药技术有限公司 | A kind of icatibant composition for injection and preparation method thereof and preparation |
| KR102099509B1 (en) | 2018-07-27 | 2020-04-09 | 강경순 | Supports for fruit trees |
| CN111944016B (en) * | 2020-08-25 | 2022-04-29 | 台州吉诺生物科技有限公司 | Preparation method of icatibant acetate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0031741A1 (en) * | 1979-12-07 | 1981-07-08 | SCIENCE UNION ET Cie SOCIETE FRANCAISE DE RECHERCHE MEDICALE | Substituted imino-acids, process for their preparation and their use as enzyme inhibitors |
| EP0052870A1 (en) * | 1980-11-25 | 1982-06-02 | Hoechst Aktiengesellschaft | Amino acid derivatives and processes for their preparation |
| DE3227055A1 (en) * | 1982-07-20 | 1984-01-26 | Hoechst Ag, 6230 Frankfurt | NEW DERIVATIVES OF 2-AZA-BICYCLO (2.2.2) OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF, AND 2-AZA-BICYCLO (2.2.2) OCTAN-3-CARBONIC ACID AS ANSWER FOR THEIR PRODUCTION |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2575753B1 (en) * | 1985-01-07 | 1987-02-20 | Adir | NOVEL PEPTIDE DERIVATIVES WITH NITROGEN POLYCYCLIC STRUCTURE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US4693993A (en) * | 1985-06-13 | 1987-09-15 | Stewart John M | Bradykinin antagonist peptides |
-
1989
- 1989-08-03 IE IE252289A patent/IE63490B1/en not_active IP Right Cessation
- 1989-08-04 DK DK198903840A patent/DK175344B1/en active Protection Beyond IP Right Term
- 1989-08-08 NO NO893193A patent/NO177597C/en not_active IP Right Cessation
- 1989-08-08 FI FI893738A patent/FI94353C/en active Protection Beyond IP Right Term
- 1989-08-08 NZ NZ230244A patent/NZ230244A/en unknown
- 1989-08-09 AU AU39431/89A patent/AU612054B2/en not_active Expired
- 1989-08-09 CA CA000607853A patent/CA1340667C/en not_active Expired - Lifetime
- 1989-08-11 IL IL9129889A patent/IL91298A/en unknown
- 1989-08-21 SK SK4906-89A patent/SK279315B6/en unknown
- 1989-08-21 CZ CS894906A patent/CZ282384B6/en not_active IP Right Cessation
- 1989-08-23 HU HU894323A patent/HU210566B/en unknown
- 1989-08-28 JP JP1218758A patent/JPH07121956B2/en not_active Expired - Lifetime
- 1989-09-11 CN CN89107065A patent/CN1035006C/en not_active Expired - Lifetime
- 1989-09-11 KR KR1019890013102A patent/KR0139632B1/en not_active Expired - Lifetime
- 1989-09-11 PT PT91692A patent/PT91692B/en not_active IP Right Cessation
- 1989-11-21 DE DE122008000066C patent/DE122008000066I2/en active Active
- 1989-11-21 DE DE3938751A patent/DE3938751A1/en not_active Withdrawn
- 1989-11-21 DE DE58907889T patent/DE58907889D1/en not_active Expired - Lifetime
- 1989-11-21 AT AT89121498T patent/ATE107318T1/en active
- 1989-11-21 EP EP89121498A patent/EP0370453B1/en not_active Expired - Lifetime
- 1989-11-21 ES ES89121498T patent/ES2057071T3/en not_active Expired - Lifetime
-
1990
- 1990-07-30 PH PH40920A patent/PH31009A/en unknown
-
1992
- 1992-06-24 MX MX9203277A patent/MX9203277A/en active IP Right Grant
- 1992-12-23 LV LVP-92-701A patent/LV10720B/en unknown
-
1995
- 1995-01-20 HU HU95P/P00069P patent/HU210712A9/en active Protection Beyond IP Right Term
-
1998
- 1998-02-20 CY CY202898A patent/CY2028A/en unknown
- 1998-06-22 HK HK98105867A patent/HK1006716A1/en not_active IP Right Cessation
-
2008
- 2008-09-09 NL NL300359C patent/NL300359I2/en unknown
- 2008-10-30 NO NO2008016C patent/NO2008016I2/en unknown
- 2008-11-19 LU LU91499C patent/LU91499I2/en unknown
- 2008-12-30 CY CY200800022C patent/CY2008022I1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0031741A1 (en) * | 1979-12-07 | 1981-07-08 | SCIENCE UNION ET Cie SOCIETE FRANCAISE DE RECHERCHE MEDICALE | Substituted imino-acids, process for their preparation and their use as enzyme inhibitors |
| EP0052870A1 (en) * | 1980-11-25 | 1982-06-02 | Hoechst Aktiengesellschaft | Amino acid derivatives and processes for their preparation |
| DE3227055A1 (en) * | 1982-07-20 | 1984-01-26 | Hoechst Ag, 6230 Frankfurt | NEW DERIVATIVES OF 2-AZA-BICYCLO (2.2.2) OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF, AND 2-AZA-BICYCLO (2.2.2) OCTAN-3-CARBONIC ACID AS ANSWER FOR THEIR PRODUCTION |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU612054B2 (en) | Peptides having bradykinin antagonist action | |
| AU638735B2 (en) | Peptides having bradykinin antagonist action | |
| US5597803A (en) | Bradykinin peptides with modifications at the N terminus | |
| US5648333A (en) | Peptides having bradykinin antagonist action | |
| CN1034416C (en) | Peptides with bradykinin-antagonistic action | |
| CN1034416Y (en) | Preparation method of peptide with bradykinin antagonism | |
| RU2083586C1 (en) | Peptides and their physiologically acceptable salts |